ClinicalTrials.Veeva

Find clinical trials for Lymphoma in London, England

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

B-Cell Lymphoma
Leukemia
Non-Hodgkin Lymphoma
Lymphoid Leukemia
Diffuse Large B-Cell Lymphoma
Precursor Cell Lymphoblastic Leukemia-Lymphoma
B-Cell Chronic Lymphocytic Leukemia

Lymphoma trials near London, England, GBR:

Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy (REFRACT)

available, in patients with relapsed or refractory follicular lymphoma. This will be done by comparing patients who have received a new trea...

Enrolling
Relapsed Follicular Lymphoma
Refractory Follicular Lymphoma
Drug: Epcoritamab
Drug: Obinutuzumab

Phase 2

University of Birmingham

London, United Kingdom and 24 other locations

multicenter Phase II study of capivasertib administered orally in participants with Relapsed or Refractory (R/R) B-cell Non-Hodgkin's Lymphoma...

Active, not recruiting
Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Drug: Capivasertib

Phase 2

AstraZeneca
AstraZeneca

Sutton, United Kingdom and 16 other locations

or carry cancer-killing substances to them. It is not yet known whether rituximab is more effective than observation in treating non-Hodgkin's lymphoma...

Active, not recruiting
Lymphoma
Biological: rituximab
Other: No treatment

Phase 3

University College London (UCL)
University College London (UCL)

London, England, United Kingdom and 71 other locations

with previously untreated CD20 positive Diffuse Large B-cell Lymphoma (DLBCL) requiring full course chemoimmunotherapy.All patients will rec...

Enrolling
Diffuse Large B Cell Lymphoma
Drug: R-CHOP + acalabrutinib
Drug: R-CHOP

Phase 2

University Hospital Southampton NHS Foundation Trust

London, United Kingdom and 32 other locations

First-in-human, open-label, sequential dose escalation and expansion study of CPI-0209 in patients with advanced solid tumors and lymphomas....

Enrolling
Lymphoma, T-Cell
Diffuse Large B Cell Lymphoma
Drug: CPI-0209

Phase 1, Phase 2

Constellation Pharmaceuticals

Sutton, United Kingdom and 50 other locations

TrAVeRse is a multicentre, open-label, randomised, Phase II study of AVR in treatment naïve MCL participants. The primary objective will be to assess...

Enrolling
Mantle Cell Lymphoma (MCL)
Drug: Venetoclax
Drug: Rituximab

Phase 2

AstraZeneca
AstraZeneca

London, United Kingdom and 47 other locations

The primary objective of this study is to characterize the safety and tolerability of loncastuximab tesirine in combination with polatuzumab vedotin,...

Enrolling
Refractory B-Cell Non-Hodgkin Lymphoma
Relapsed B-Cell Non-Hodgkin Lymphoma
Drug: Mosunetuzumab
Drug: Obinutuzumab

Phase 1

ADC Therapeutics

London, United Kingdom and 26 other locations

This study will characterize the safety and clinical benefit of valemetostat tosylate in participants with relapsed/refractory peripheral T-cell lymphoma...

Active, not recruiting
Relapsed/Refractory Peripheral T-Cell Lymphoma
Adult T Cell Leukemia/Lymphoma
Drug: Valemetostat Tosylate

Phase 2

Daiichi Sankyo

London, United Kingdom and 59 other locations

dose of BGB-11417 monotherapy for relapsed or refractory mantle cell lymphoma. Part 2 evaluates efficacy of BGB-11417 monotherapy at the rec...

Enrolling
Mantle Cell Lymphoma
Relapsed Mantle Cell Lymphoma
Drug: BGB-11417

Phase 1, Phase 2

BeiGene
BeiGene

London, United Kingdom and 95 other locations

Of Care in adult patients with aggressive B-cell Non-Hodgkin Lymphoma after failure of rituximab and anthracycline containing frontline immu...

Active, not recruiting
Non-Hodgkin Lymphoma
Drug: Tisagenlecleucel after optional bridging and lymphodepleting chemotherapy
Drug: Platinum-based immunochemotherapy followed in responding patients with high dose chemotherapy and autologous hematopoietic stem cell transplant (HSCT)

Phase 3

Novartis
Novartis

London, United Kingdom and 66 other locations

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems